Published in 1996
The PsARC was developed as a PsA-speciﬁc composite responder index speciﬁcally for a study of sulfasalazine in PsA (Clegg DO et Co. 1996). It was ﬁrst named the PsARC in a subsequent trial of etanercept in PsA (Mease PJ et co. 2000).
A modiﬁcation of the PsARC using patient and physician global improvement measured by a visual analog scale has been employed and considered acceptable by regulatory agencies (Mease PJ, et al, for the Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double- blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279–89).
Clegg DO; Alepa FP; Luggen ME; Cohen MR; Makkena R; Haakenson CM; Ward RH; Manaster BJ; Anderson RJ; Ward JR; Silverman SL; Schumacher HR Jr; Cush JJ; Reda DJ; Mejias E; Cannon GW; Weisman MH; Taylor T; Budiman-Mak E; Blackburn WD; Vasey FB; Mahowald ML; Henderson WG
Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996;39: 2013–20 (PubMed abstract)
Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etan ercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356:385–90 (PubMed abstract)